Literature DB >> 28243973

Presence of headache and headache types in patients with tumors of the sellar region-can surgery solve the problem? Results of a prospective single center study.

Sonja Siegel1, Renata Weber Carneiro2, Michael Buchfelder3, Bernadette Kleist1, Agnieszka Grzywotz1, Rolf Buslei4, Ulrike Bingel5, Georg Brabant6, Thomas Schenk7, Ilonka Kreitschmann-Andermahr8.   

Abstract

PURPOSE: Headache is a common presenting feature of patients with pituitary adenomas and other tumors of the sellar region. However, at present, it still is unclear whether the headache is actually caused by the tumor. To explore whether there is a relation, we examined in detail the headache types, their relationship to the underlying pathology, and if the headache responded to neurosurgery in a prospective study design.
METHODS: One hundred twelve patients with tumors of the sellar region scheduled for neurosurgery in a single center were analyzed for presence and quality of headache before surgery and at least 3 months after surgery. Patients received headache and depression self-rating inventories, presented on a handheld computer (PainDetect®). Clinical variables thought to impact on headache were analyzed in conjunction with the inventories.
RESULTS: Fifty-nine (53%) patients reported headache in the 3 months prior to neurosurgery, 49 (44%) had headache at the time of filling in the questionnaires. The four patients with pituitary apoplexy described thunderclap headache. In the other patients diverse headache types were encountered, most frequently migraine. Untreated gonadotroph deficiency was significantly associated with absence of headache, while none of the other clinical and morphological variables related to headache. Presence of headache and disability due to headache were not significantly reduced after surgery.
CONCLUSION: Apart from pituitary apoplexy we detected no specific headache type in our patient group and no significant improvement of headache after neurosurgery. Headache alone constitutes neither a valid diagnostic marker for the presence of tumors of the sellar region nor a sufficient indication for tumor removal.

Entities:  

Keywords:  Headache; Neurosurgery; Pituitary adenoma; Sellar region

Mesh:

Year:  2017        PMID: 28243973     DOI: 10.1007/s12020-017-1266-9

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  31 in total

1.  Headache associated with pituitary adenomas.

Authors:  T Abe; K Matsumoto; J Kuwazawa; I Toyoda; K Sasaki
Journal:  Headache       Date:  1998 Nov-Dec       Impact factor: 5.887

2.  Paper versus electronic rating scales for pain assessment: a prospective, randomised, cross-over validation study with 200 chronic pain patients.

Authors:  Uwe Junker; Rainer Freynhagen; Klaus Längler; Ulrich Gockel; Uwe Schmidt; Thomas R Tölle; Ralf Baron; Thomas Kohlmann
Journal:  Curr Med Res Opin       Date:  2008-05-15       Impact factor: 2.580

3.  Headache in patients with pituitary adenoma: clinical and paraclinical findings.

Authors:  Christoph J Schankin; Anna K Reifferscheid; Markus Krumbholz; Jennifer Linn; Walter Rachinger; Sigrid Langer; Petra Sostak; Thomas Arzberger; Hans Kretzschmar; Andreas Straube
Journal:  Cephalalgia       Date:  2012-10-11       Impact factor: 6.292

4.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

Review 5.  Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability.

Authors:  W F Stewart; R B Lipton; A J Dowson; J Sawyer
Journal:  Neurology       Date:  2001       Impact factor: 9.910

6.  Clinical characteristics and risk factors for headache associated with non-functioning pituitary adenomas.

Authors:  Bin Yu; Nan Ji; Yun Ma; Bao Yang; Peng Kang; Fang Luo
Journal:  Cephalalgia       Date:  2016-05-06       Impact factor: 6.292

7.  The clinical characteristics of headache in patients with pituitary tumours.

Authors:  M J Levy; M S Matharu; K Meeran; M Powell; P J Goadsby
Journal:  Brain       Date:  2005-05-11       Impact factor: 13.501

Review 8.  Migraine and its psychiatric comorbidities.

Authors:  Mia Tova Minen; Olivia Begasse De Dhaem; Ashley Kroon Van Diest; Scott Powers; Todd J Schwedt; Richard Lipton; David Silbersweig
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-01-05       Impact factor: 10.154

9.  Pituitary volume and headache: size is not everything.

Authors:  Miles J Levy; H Rolf Jäger; Michael Powell; Manjit S Matharu; Karim Meeran; Peter J Goadsby
Journal:  Arch Neurol       Date:  2004-05

10.  Headache in brain tumor: a cross-sectional study.

Authors:  N Suwanwela; K Phanthumchinda; S Kaoropthum
Journal:  Headache       Date:  1994 Jul-Aug       Impact factor: 5.887

View more
  4 in total

Review 1.  Headaches in Patients with Pituitary Tumors: a Clinical Conundrum.

Authors:  Laura E Donovan; Mary R Welch
Journal:  Curr Pain Headache Rep       Date:  2018-07-04

2.  Headache Before and After Endoscopic Transsphenoidal Pituitary Tumor Surgery: A Prospective Study.

Authors:  Agnes Andersson; Tobias Hallén; Daniel S Olsson; Dan Farahmand; Ann-Charlotte Olofsson; Eva Jakobsson Ung; Sofie Jakobsson; Henrik Bergquist; Gudmundur Johannsson; Oskar Ragnarsson; Thomas Skoglund
Journal:  J Neurol Surg B Skull Base       Date:  2021-05-29

3.  Is pituitary MRI screening necessary in cluster headache?

Authors:  Lou Grangeon; Emer O'Connor; Daisuke Danno; Thanh Mai Pham Ngoc; Sanjay Cheema; Erling Tronvik; Indran Davagnanam; Manjit Matharu
Journal:  Cephalalgia       Date:  2021-01-06       Impact factor: 6.292

4.  Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members' View in an AIP Mutation-Positive Family.

Authors:  Pedro Marques; Sayka Barry; Amy Ronaldson; Arla Ogilvie; Helen L Storr; Peter J Goadsby; Michael Powell; Mary N Dang; Harvinder S Chahal; Jane Evanson; Ajith V Kumar; Joan Grieve; Márta Korbonits
Journal:  Int J Endocrinol       Date:  2018-04-04       Impact factor: 2.803

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.